Overview. Cancer research at Duke is a vibrant, interactive and dynamic enterprise. Eleven major research programs have significant peer-reviewed funding, but are operationally optimized only with coordinated activities and communication provided by DCCC. The DCCC serves this vital role which facilitates interprogrammatic and intraprogrammatie interactions of the research programs, and allows early entry into the development pathway towards clinical trials of promising new strategies. In addition, the ability of investigators to take observations in the clinic back to the laboratory is facilitated by the DCCC. The DCCC is central to the complex coordination of activities essential to contemporary cancer research, and makes possible many activities that would be far too complex to organize without the support of the CCSG. In the last review, this component of the CCSG was rated Good to Acceptable. Significant concerns were raised about the lack of details regarding the function and role of the External Scientific Advisory Committee, the Annual Meeting, and annual Program Retreats. It was recommended that the DCCC provide more details about the planning and evaluation process, with the establishment of long- term goals, mission statement and strategic plan. Planning is a major priority for the new DCCC leadership, and it is has been a major emphasis over the past months. Current Planning and Evaluation activities and plans for the future are described below. The DCCC has made a major effort to strengthen several areas of research based on criticisms in the Summary Statement from the previous review. This involved several planning meetings of individual Programs, Shared Resource Advisory Committees and other groups to generate long-term goals. Input was also obtained from strategic planning processes that have involved o if-campus retreats by senior leadership and input from the DCCC ESAC. Areas that were addressed include recruitment of new faculty and commitment of DCCC resources to build strength in Programs and Programs-in-Development, development of new Shared Resources, reviews of past performance, and recommendations for future directions.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014236-34
Application #
7726654
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2008-01-01
Budget End
2008-12-31
Support Year
34
Fiscal Year
2008
Total Cost
$76,600
Indirect Cost
Name
Duke University
Department
Type
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Xu, Yinghui; Wang, Yanru; Liu, Hongliang et al. (2018) Genetic variants in the metzincin metallopeptidase family genes predict melanoma survival. Mol Carcinog 57:22-31
Abdi, Khadar; Kuo, Chay T (2018) Laminating the mammalian cortex during development: cell polarity protein function and Hippo signaling. Genes Dev 32:740-741
Lu, Min; Sanderson, Sydney M; Zessin, Amelia et al. (2018) Exercise inhibits tumor growth and central carbon metabolism in patient-derived xenograft models of colorectal cancer. Cancer Metab 6:14
Qian, Danwen; Liu, Hongliang; Wang, Xiaomeng et al. (2018) Potentially functional genetic variants in the complement-related immunity gene-set are associated with non-small cell lung cancer survival. Int J Cancer :
Ashcraft, Kathleen A; Choudhury, Kingshuk Roy; Birer, Sam R et al. (2018) Application of a Novel Murine Ear Vein Model to Evaluate the Effects of a Vascular Radioprotectant on Radiation-Induced Vascular Permeability and Leukocyte Adhesion. Radiat Res 190:12-21
Ong, Cecilia T; Campbell, Brittany M; Thomas, Samantha M et al. (2018) Metaplastic Breast Cancer Treatment and Outcomes in 2500 Patients: A Retrospective Analysis of a National Oncology Database. Ann Surg Oncol 25:2249-2260
Duan, Bensong; Hu, Jiangfeng; Liu, Hongliang et al. (2018) Genetic variants in the platelet-derived growth factor subunit B gene associated with pancreatic cancer risk. Int J Cancer 142:1322-1331
Wu, Mengxi; Huang, Po-Hsun; Zhang, Rui et al. (2018) Circulating Tumor Cell Phenotyping via High-Throughput Acoustic Separation. Small 14:e1801131
Vlahovic, Gordana; Meadows, Kellen L; Hatch, Ace J et al. (2018) A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer. Oncologist 23:782-790
Xu, Yinghui; Liu, Hongliang; Liu, Shun et al. (2018) Genetic variant of IRAK2 in the toll-like receptor signaling pathway and survival of non-small cell lung cancer. Int J Cancer 143:2400-2408

Showing the most recent 10 out of 513 publications